Summit Therapeutics (SMMT) Equity Ratio (2017 - 2026)
Summit Therapeutics filings provide 10 years of Equity Ratio readings, the most recent being 0.84 for Q1 2026.
- Quarterly Equity Ratio fell 6.07% to 0.84 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.84 through Mar 2026, down 6.07% year-over-year, with the annual reading at 0.88 for FY2025, 1.73% down from the prior year.
- Equity Ratio hit 0.84 in Q1 2026 for Summit Therapeutics, down from 0.88 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.9 in Q1 2025 and bottomed at 0.19 in Q4 2022.
- Average Equity Ratio over 5 years is 0.63, with a median of 0.57 recorded in 2024.
- The largest annual shift saw Equity Ratio plummeted 74.04% in 2022 before it soared 258.72% in 2025.
- Summit Therapeutics' Equity Ratio stood at 0.19 in 2022, then skyrocketed by 100.75% to 0.38 in 2023, then surged by 133.15% to 0.89 in 2024, then fell by 1.73% to 0.88 in 2025, then decreased by 3.92% to 0.84 in 2026.
- Per Business Quant, the three most recent readings for SMMT's Equity Ratio are 0.84 (Q1 2026), 0.88 (Q4 2025), and 0.73 (Q3 2025).